NicOx

Focus: NicOx is a French biotech company founded in 1894 specializing in nitric oxide donation technology for therapeutic applications. The company operates as a public entity with a focused platform approach to drug development.

Ophthalmology Nephrology Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NicOx

AI assessmentNot Hiring

No open roles listed right now. Follow NicOx to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

6 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ADenoVirus Initiative Study in Epidemiology in Italy

Viral Conjunctivitis

N/A

Clinical Trials (1)

NCT03055065ADenoVirus Initiative Study in Epidemiology in Italy

N/A

Help build intelligence for NicOx

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Unique nitric oxide donation platform offers differentiated scientific expertise and IP moat in underexplored modality
Established public company with 130+ year history provides stability and resources for long-term R&D careers
French headquarters in Biot provides access to European biotech ecosystem and regulatory pathways

Watch Out For

Zero active clinical trials and empty pipeline signal stalled development momentum and limited near-term catalysts
No current job openings indicate potential headcount freezes or restructuring phases ahead
Minimal disclosed financial data and sparse publications suggest limited visibility into company health and scientific output

Generated by Claude from NicOx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ADenoVirus Initiative Study in Epidemiology in France

Viral Conjunctivitis

N/A

Clinical Trials (1)

NCT02054234ADenoVirus Initiative Study in Epidemiology in France

N/A

ADenoVirus Initiative Study in Epidemiology in Spain

Viral Conjunctivitis

N/A

Clinical Trials (1)

NCT02254330ADenoVirus Initiative Study in Epidemiology in Spain

N/A

ADenoVirus Initiative Study in Epidemiology in UK

Viral Conjunctivitis

N/A

Clinical Trials (1)

NCT02112773ADenoVirus Initiative Study in Epidemiology in UK

N/A

ADenoVirus Initiative Study in Epidemiology in Germany

Viral Conjunctivitis

N/A

Clinical Trials (1)

NCT02054273ADenoVirus Initiative Study in Epidemiology in Germany

N/A

naproxcinod

Liver Disease

Phase 1

Clinical Trials (1)

NCT00621881A Phase 1 Study to Compare the PK and Safety of Naproxcinod in Hepatic Impaired Patients and Matching Healthy Subjects

Phase 1

naproxcinod 750 bid

Pharmacokinetics

Phase 1

Clinical Trials (1)

NCT01404598Pharmacokinetics Study: Determination of Naproxcinod and Its Metabolites After Oral Administration in Male

Phase 1

naproxcinod 375 mg bid

Osteoarthritis

Phase 1

Clinical Trials (1)

NCT00662896To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension

Phase 1

naproxcinod

Renal Hemodynamics

Phase 1

Clinical Trials (1)

NCT00909519Effect of Repeated Dosing of Naproxcinod on Renal Hemodynamic and on Sodium Balance in Healthy Volunteers Before and After a Single Dose of Furosemide

Phase 1

naproxcinod

Renal Failure

Phase 1

Clinical Trials (1)

NCT00674856A Pharmacokinetics and Safety Study of Naproxcinod in Subjects With Impaired Renal Function

Phase 1

naproxcinod 375 mg -750 mg -1125 mg bid

Osteoarthritis

Phase 1

Clinical Trials (1)

NCT00662610A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

Phase 1

NCX 4251

Blepharitis

Phase 2

Clinical Trials (1)

NCT04675242Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

Phase 2

Iota-Carrageenan

Adenoviral Conjunctivitis

Phase 2

Clinical Trials (1)

NCT03009799Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)

Phase 2

PF-03187207 and Latanoprost Vehicle

Primary Open Angle Glaucoma

Phase 2

Clinical Trials (1)

NCT00441883Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Phase 2

NCX 470

Glaucoma, Open-Angle

Phase 2

Clinical Trials (1)

NCT03657797Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 2

NCX-4016

Intermittent Claudication

Phase 2

Clinical Trials (1)

NCT01256775Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)

Phase 2

Fluticasone Propionate

Blepharitis

Phase 2

Clinical Trials (1)

NCT03926026Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis